Clinical application of drug delivery systems in cancer chemotherapy: Review of the efficacy and side effects of approved drugs

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 5, 2013, Pages 715-718

  Iwamoto, Takuya ^a  

^a MIE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Albumin bound paclitaxel; Drug delivery system; Liposomal doxorubicin; Side effect

Indexed keywords

BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; PACLITAXEL; TOPOTECAN; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AIDS RELATED KAPOSI SARCOMA; ANEMIA; ANOREXIA; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; DIARRHEA; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPITHELIAL OVARIAN CARCINOMA; HAND FOOT SYNDROME; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERSENSITIVITY; JAPAN; KAPOSI SARCOMA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOMATOUS MENINGITIS; MENINGITIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVARY CANCER; OVARY CARCINOMA; OVARY METASTASIS; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

ALBUMINS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 84876940723     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-01102     Document Type: Review

References (23)

1. Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ, International Pegylated Liposomal Doxorubicin Study Group. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J. Clin. Oncol., 16, 683-691 (1998).
2. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol., 16, 2445-2451 (1998).
3. Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, Ambinder RF, Lee JY, Krown SE, Sparano JA. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer, 116, 3969-3977 (2010).
4. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol., 19, 3312-3322 (2001).
5. Fujisaka Y, Tamura T, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, Nokihara H, Horiike A, Kodama T, Saijo N. Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients. Jpn. J. Clin. Oncol., 36, 477-482 (2006).
6. Katsumata N, Fujiwara Y, Kamura T, Nakanishi T, Hatae M, Aoki D, Tanaka K, Tsuda H, Kamiura S, Takehara K, Sugiyama T, Kigawa J, Fujiwara K, Ochiai K, Ishida R, Inagaki M, Noda K. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group. Jpn. J. Clin. Oncol., 38, 777-785 (2008).
7. Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, Lorusso D, Cognetti F, Vernaglia Lombardi A, Gebbia V, Scollo P, Morabito A, Signoriello G, Perrone F. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. Oncology, 76, 49-54 (2009).
8. Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM Jr, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol. Oncol., 116, 323-325 (2010).
9. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol., 28, 3323-3329 (2010).
10. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J. Clin. Oncol., 25, 3892-3901 (2007).
11. Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ, DOXIL-MMY-3001 Study Investigators. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer, 112, 1529-1537 (2008).
12. Takamatsu Y, Sunami K, Hata H, Nagafuji K, Choi I, Higuchi M, Uozumi K, Masaki Y, Tamura K, Kyushu Hematology Organization for Treatment Study Group (K-HOT). A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma. Int. J. Hematol., 92, 503-509 (2010).
13. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol., 23, 7794-7803 (2005).
14. Yamada K, Yamamoto N, Yamada Y, Mukohara T, Minami H, Tamura T. Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors. Jpn. J. Clin. Oncol., 40, 404-411 (2010).
15. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res., 11, 4136-4143 (2005).
16. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J. Clin. Oncol., 30, 2055-2062 (2012).
17. Chan A, Shih V, Tham Chee K. Liposomal doxorubicin-associated acute hypersensitivity despite appropriate preventive measures. J. Oncol. Pharm. Pract., 13, 105-107 (2007).
18. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res., 8, 1038-1044 (2002).
19. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol., 14, 2353-2364 (1996).
20. Latagliata R, Breccia M, Fazi P, Iacobelli S, Martinelli G, Di Raimondo F, Sborgia M, Fabbiano F, Pirrotta MT, Zaccaria A, Amadori S, Caramatti C, Falzetti F, Candoni A, Mattei D, Morselli M, Alimena G, Vignetti M, Baccarani M, Mandelli F. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br. J. Haematol., 143, 681-689 (2008).
21. Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, Phuphanich S, Rogers LR, Gutheil JC, Batchelor T, Lyter D, Chamberlain M, Maria BL, Schiffer C, Bashir R, Thomas D, Cowens W, Howell SB. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol., 17, 3110-3116 (1999).
22. Yamamoto Y, Kawano I, Iwase H. nab-Paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther, 4, 123-136 (2011).
23. Rodriguez MA, Pytlik R, Kozak T, Chhanabhai M, Gascoyne R, Lu B, Deitcher SR, Winter JN, Marqibo Investigators. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer, 115, 3475-3482 (2009).